Symphogen's Series E Round

Symphogen raised a round of funding on February 06, 2009. Investors include New Science Ventures.

Symphogen is developing next-generation antibody therapeutics for the treatment of cancer and is dedicated to bringing truly innovative oncology products to the market. The company has advanced the fr…

Articles about Symphogen's Series E Round: